Prognostic implication of stress hyperglycemia in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Table 2 Association between glucose/GA ratio and all-cause and cardiovascular mortality

Outcome	Cases, No	Incidence Rate, per 1000 Person-Years	HR (95% CI)
Outcome	Cases, No	Incidence Rate, per 1000 Person-Years	Model 1 ^a	Model 2 ^b	Model 3 ^c
All-cause mortality
Glucose/GA ratio, quartiles^d
Q1	107	24.1	1.63 (1.17–2.25)	1.54 (1.10–2.14)	1.43 (1.01–2.03)
Q2	55	12.2	1 [Reference]	1 [Reference]	1 [Reference]
Q3	71	15.2	1.40 (0.98–1.98)	1.44 (1.01–2.06)	1.33 (0.91–1.95)
Q4	80	18.0	1.86 (1.32–2.63)	1.60 (1.11–2.29)	1.51 (1.03–2.21)
Cardiovascular mortality
Glucose/GA ratio, quartiles
Q1	60	13.5	1.77 (1.13–2.78)	1.69 (1.07–2.69)	1.51 (0.94–2.43)
Q2	28	6.2	1 [Reference]	1 [Reference]	1 [Reference]
Q3	38	8.1	1.48 (0.91–2.41)	1.52 (0.92–2.50)	1.41 (0.84–2.35)
Q4	51	11.5	2.34 (1.47–3.72)	1.97 (1.21–3.20)	1.69 (1.02–2.79)

CI, confidence interval; GA, glycated albumin; and HR, hazard ratio
^a Model 1 was adjusted for age and sex
^b Model 2 was adjusted as model 1 plus BMI, smoking status, diabetes, hypertension, dyslipidemia, previous myocardial infarction, previous PCI, previous stroke, and AMI
^c Model 3 was adjusted as model 2 plus left main coronary artery or three‑vessel disease, eGFR, SBP, heart rate, LVEF < 50%, hs-CRP, albumin, hemoglobin, ACEI/ARB at discharge, and β-blocker at discharge
^d Quartiles of glucose/GA ratio, Q1 < 0.334, Q2 = 0.334–0.384, Q3 = 0.385–0.442, Q4 > 0.442

ISSN: 1475-2840